Last updated: September 5, 2026
The fixed-dose triple combination of aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide was marketed in the United States as Amturnide by Novartis. Its commercial trajectory was short and unfavorable. The product entered a mature hypertension market dominated by inexpensive generic therapies, while the aliskiren franchise later faced major clinical and regulatory restrictions after the ALTITUDE trial. Amturnide no longer has a meaningful commercial presence in the United States, and its revenue contribution is not separately disclosed by Novartis.
What drug contains aliskiren, amlodipine, and hydrochlorothiazide?
Amturnide combined three antihypertensive mechanisms in one tablet:
| Component |
Drug class |
Primary role |
| Aliskiren hemifumarate |
Direct renin inhibitor |
Suppresses renin-angiotensin system activity |
| Amlodipine besylate |
Dihydropyridine calcium-channel blocker |
Produces arterial vasodilation |
| Hydrochlorothiazide |
Thiazide diuretic |
Increases sodium and fluid excretion |
The product was approved by the U.S. Food and Drug Administration for hypertension in adults who were not adequately controlled on dual therapy or who required all three components at their individual doses.[1]
Novartis also marketed related products:
- Tekturna: aliskiren tablets
- Tekturna HCT: aliskiren/hydrochlorothiazide
- Exforge: amlodipine/valsartan
- Exforge HCT: amlodipine/valsartan/hydrochlorothiazide
- Amturnide: aliskiren/amlodipine/hydrochlorothiazide
Amturnide was positioned as a step-up therapy for patients requiring three antihypertensive agents. Its commercial rationale depended on the premise that improved adherence from once-daily combination therapy would support premium pricing over separate generic tablets.
When was Amturnide approved and discontinued?
Amturnide received FDA approval in January 2010 under New Drug Application 022166.[1] Its commercial life was constrained by the subsequent decline of aliskiren as a treatment platform.
| Event |
Date |
Commercial significance |
| Tekturna approval |
2007 |
Established aliskiren franchise |
| Amturnide FDA approval |
January 2010 |
Added triple-combination product |
| ALTITUDE trial stopped |
December 2011 |
Raised safety and efficacy concerns for aliskiren |
| FDA safety communication on aliskiren combinations |
April 2012 |
Restricted use with ACE inhibitors and ARBs in certain patients |
| Novartis curtailed aliskiren development and marketing |
2012-2013 |
Reduced promotional support and physician adoption |
| Amturnide U.S. commercial availability |
Discontinued |
Removed the principal branded triple-combination product |
The ALTITUDE trial evaluated aliskiren added to standard therapy with an ACE inhibitor or angiotensin-receptor blocker in patients with type 2 diabetes and renal impairment or cardiovascular disease. The trial was stopped early after the independent monitoring committee identified increased risks without demonstrated clinical benefit.[2]
The FDA subsequently warned against combining aliskiren with ACE inhibitors or ARBs in patients with diabetes and advised avoidance in patients with moderate-to-severe renal impairment.[3] These restrictions directly affected the credibility of aliskiren as the foundation of a broad hypertension franchise.
What was the financial trajectory of the aliskiren franchise?
Novartis did not separately report Amturnide revenue. Public financial disclosures generally grouped Tekturna, Rasilez, and related products or included them within broader cardiovascular categories. The available financial pattern is therefore a franchise-level assessment rather than a product-level revenue series.
Early growth phase
Aliskiren entered the market with a differentiated mechanism and a large target population. Novartis promoted it as the first direct renin inhibitor approved for hypertension in the United States. Initial commercial expectations were based on:
- A large global hypertension population
- Use as monotherapy or add-on therapy
- Combination opportunities with amlodipine, hydrochlorothiazide, and valsartan
- Potential premium pricing relative to older generic agents
The franchise did not achieve the scale of Novartis products such as Diovan, Exforge, or later oncology and immunology products. Generic competition in calcium-channel blockers and thiazide diuretics limited the economic value of the combination platform.
Erosion phase
The ALTITUDE outcome changed the investment profile. The safety signal weakened physician confidence in aliskiren, especially among patients with diabetes, kidney disease, and cardiovascular risk. These were important segments for intensive hypertension treatment.
The commercial effect extended beyond Amturnide:
- Aliskiren monotherapy became less attractive relative to established agents.
- Combination products lost their platform advantage because one component carried regulatory restrictions.
- Clinical development and promotional investment declined.
- The related aliskiren/valsartan product Valturna was withdrawn from the U.S. market.
- Amturnide faced competition from cheaper and more familiar three-drug regimens.
Mature and post-commercial phase
By the time Amturnide was discontinued, the product had limited ability to compete with generic combinations. A patient could receive equivalent blood-pressure-lowering therapy using separate tablets containing generic amlodipine, hydrochlorothiazide, and an ACE inhibitor, ARB, or other agent.
The economic result was a rapid transition from branded growth opportunity to low-value legacy asset. Novartis no longer presents Amturnide as a material revenue contributor in its public reporting. Current revenue exposure is effectively zero in the U.S. branded market.
How did Amturnide compare with competing hypertension therapies?
Amturnide competed against both branded fixed-dose combinations and generic multidrug regimens.
| Product or regimen |
Components |
Market position |
Cost pressure |
| Amturnide |
Aliskiren/amlodipine/HCTZ |
Differentiated triple therapy |
High |
| Exforge HCT |
Amlodipine/valsartan/HCTZ |
Established branded triple therapy |
Moderate to high |
| Generic amlodipine plus HCTZ plus ARB |
Three separate tablets |
Widely used standard approach |
Low |
| Generic amlodipine/benazepril plus HCTZ |
Combination-based regimen |
Mature generic alternative |
Very low |
| Generic ACE inhibitor or ARB plus amlodipine and HCTZ |
Three-drug regimen |
Broad physician familiarity |
Very low |
Amturnide's adherence argument was commercially credible, but its value proposition was weakened by the low price of separate generic tablets. Fixed-dose combinations can improve pill burden, but the benefit must offset formulary restrictions, copay differences, and concerns about dose flexibility.
The product also lacked a strong clinical differentiation claim. Aliskiren did not establish superior cardiovascular outcomes over ACE inhibitors or ARBs. Without outcome superiority, the triple combination was exposed to substitution by inexpensive standard therapies.
What FDA regulatory restrictions affected aliskiren?
The main regulatory risk involved dual blockade of the renin-angiotensin system.
The FDA labeling for aliskiren products warned against use with ACE inhibitors or ARBs in patients with diabetes. It also advised avoiding such combinations in patients with renal impairment. The risks included:
- Hypotension
- Hyperkalemia
- Renal impairment
- Renal failure
- Possible adverse cardiovascular outcomes in high-risk populations
These restrictions did not prohibit every use of aliskiren, but they narrowed the eligible population and reduced the attractiveness of combination prescribing. Many hypertensive patients receiving multiple agents already had diabetes, chronic kidney disease, or cardiovascular comorbidity, which made the warning commercially significant.
The FDA did not identify a comparable regulatory failure for amlodipine or hydrochlorothiazide. The commercial problem was concentrated in the aliskiren component and the broader clinical-development strategy.
What patents protected Amturnide and its components?
Amturnide was protected by a combination of aliskiren compound patents, formulation patents, and combination-use patents. The patent estate was materially less durable than the product's theoretical market opportunity.
The key patent categories were:
- Aliskiren active-ingredient patents
- Salt and solid-form protection for aliskiren hemifumarate
- Fixed-dose combinations with hydrochlorothiazide
- Fixed-dose combinations with amlodipine
- Triple-combination formulations
- Manufacturing and pharmaceutical-composition claims
- Method-of-use claims for treating hypertension
Patent protection did not prevent substitution by generic amlodipine and hydrochlorothiazide. A generic manufacturer could also pursue separate tablets rather than reproduce the branded triple formulation.
By the mid-2020s, the original aliskiren patent estate was no longer a meaningful U.S. commercial barrier. The principal market risk had shifted from patent expiry to the absence of demand for a branded aliskiren-based combination. Patent expiry therefore had limited incremental effect on revenue because commercial erosion had already occurred.
What was the Orange Book and Paragraph IV exposure?
Amturnide was approved as a prescription drug product under an NDA and was subject to Orange Book listing during its commercial period. The relevant patent risks included challenges to the active ingredient, combination claims, and formulation claims.
Paragraph IV litigation risk was commercially less important than in major blockbuster products for several reasons:
- Amturnide sales were modest compared with leading cardiovascular brands.
- Generic companies could avoid the triple-combination formulation by selling the components separately.
- Aliskiren's safety restrictions reduced the potential return on an abbreviated new drug application.
- The product was discontinued before a large generic-entry event could create material market disruption.
The absence of a major, high-value generic settlement involving Amturnide reflects the limited commercial attractiveness of the target rather than strong residual exclusivity.
What generic launch scenarios existed for Amturnide?
Three generic-entry scenarios were economically possible.
Scenario 1: Separate-component substitution
This was the most commercially important scenario. Physicians and payers could replace Amturnide with generic amlodipine, hydrochlorothiazide, and another antihypertensive. This substitution did not require a generic version of the exact triple tablet.
Scenario 2: Generic triple-combination launch
A manufacturer could seek approval for an aliskiren/amlodipine/hydrochlorothiazide tablet. This path would face weak demand, limited formulary value, and clinical concerns around aliskiren.
Scenario 3: Continued niche use
A small number of patients could remain on the branded or legacy regimen where aliskiren was tolerated and clinically selected. This would not support meaningful branded revenue because of product discontinuation and the availability of alternatives.
The most likely outcome was not a sudden generic cliff. It was gradual therapeutic substitution followed by commercial abandonment.
What manufacturing and intellectual-property barriers affected the product?
Manufacturing the triple product required control of three active ingredients with different formulation properties and dose ranges. The manufacturer also had to maintain:
- Content uniformity across low-dose and high-dose strengths
- Chemical stability of the fixed-dose formulation
- Dissolution performance for each component
- Bioequivalence across all strengths
- Consistent tablet compression and coating
- Compatibility with regulatory requirements for combination products
These technical requirements could raise development costs. They did not create a durable commercial moat because the components were all established oral small molecules, and generic manufacturers could use alternative tablet configurations or separate products.
The most important barrier was therefore commercial rather than manufacturing-related. The product lacked a sufficiently large, stable patient population willing to use an aliskiren-based triple regimen.
What licensing deals or strategic transactions involved Amturnide?
No major licensing transaction materially changed Amturnide's economics. Novartis controlled the principal commercial development and marketing strategy for aliskiren products. The franchise was developed through internal Novartis programs and collaborations associated with renin-inhibitor research, but Amturnide did not become the subject of a major external licensing or acquisition transaction.
The absence of a later licensing deal is consistent with the product's declining clinical and commercial value. A potential partner would have faced safety restrictions, generic competition, limited physician demand, and a discontinued U.S. brand.
How strong was the patent estate compared with the commercial opportunity?
The patent estate was technically broad but commercially weak by the end of the product's life.
| Factor |
Assessment |
| Active ingredient protection |
Historically meaningful, but expired or commercially exhausted |
| Combination protection |
Narrower and easier to bypass through separate tablets |
| Formulation protection |
Potentially useful for exact-product protection |
| Method-of-use protection |
Limited by the aliskiren safety profile |
| Manufacturing protection |
Moderate technical value, low market value |
| Generic substitution resistance |
Low |
| Litigation leverage |
Low to moderate during the active period |
| Residual 2026 franchise value |
Negligible |
The estate could delay direct replication of the exact product, but it could not prevent substitution with standard generic hypertension therapy.
What is the current competitive and financial outlook?
The current outlook for Amturnide is noncommercial. There is no meaningful branded growth case in the United States. The relevant market has moved toward generic combinations containing:
- An ACE inhibitor or ARB
- A calcium-channel blocker
- A thiazide or thiazide-like diuretic
Aliskiren remains a niche therapeutic option rather than a platform for a high-value hypertension franchise. The drug may retain limited clinical use where physicians select it for specific patients, but this does not support significant revenue.
For investors and licensing teams, the asset's value is primarily historical or analytical:
- It illustrates the risk of building a combination franchise around a differentiated mechanism without outcome superiority.
- It demonstrates how a safety signal in one component can impair an entire product family.
- It shows that formulation innovation cannot offset broad generic substitution.
- It provides little current opportunity for branded commercialization.
- It has limited strategic value unless linked to a new indication, delivery system, or materially differentiated clinical benefit.
Key Takeaways
- Amturnide combined aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide.
- Novartis received FDA approval in January 2010.
- The product competed against inexpensive generic multidrug regimens and branded amlodipine/ARB/diuretic combinations.
- The ALTITUDE trial and subsequent FDA restrictions materially damaged the aliskiren franchise.
- Amturnide was discontinued and no longer has meaningful U.S. branded revenue.
- Novartis did not separately disclose Amturnide sales.
- Patent protection did not prevent substitution with separate generic tablets.
- The principal commercial failure was weak clinical differentiation combined with safety restrictions and intense generic competition.
- Current revenue exposure and licensing value are negligible absent a new clinical or formulation strategy.
FAQs
Is Amturnide still available in the United States?
No. Amturnide is a discontinued aliskiren-based triple combination and does not have a meaningful current U.S. commercial market.
Is aliskiren safer than an ACE inhibitor or ARB?
Aliskiren has a different mechanism, but clinical evidence did not establish a broad outcome advantage over ACE inhibitors or ARBs. Its labeling restricts certain combinations with ACE inhibitors and ARBs in patients with diabetes or renal impairment.[3]
Can generic companies sell aliskiren, amlodipine, and hydrochlorothiazide separately?
Yes. Separate generic tablets can provide the same three pharmacologic components without reproducing the exact Amturnide formulation.
Did Amturnide generate blockbuster-level revenue?
No. Amturnide was not a blockbuster product, and Novartis did not report a separately disclosed revenue stream indicating material standalone sales.
Was Amturnide withdrawn because of a manufacturing defect?
The commercial decline was tied primarily to limited market adoption, generic competition, and the clinical and regulatory consequences associated with aliskiren. It was not principally a manufacturing-defect withdrawal.
References
- U.S. Food and Drug Administration. (2010). Amturnide prescribing information. https://www.accessdata.fda.gov
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Armbrecht, J., & the ALTITUDE Investigators. (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine, 367(23), 2204-2213. https://doi.org/10.1056/NEJMoa1208799
- U.S. Food and Drug Administration. (2012). FDA drug safety communication: New warning and contraindication for blood pressure medicines containing aliskiren. https://www.fda.gov/drugs/drug-safety-and-availability
- Novartis AG. (2012). Annual report 2012. https://www.novartis.com/investors/financial-data/annual-report
- Novartis AG. (2013). Annual report 2013. https://www.novartis.com/investors/financial-data/annual-report
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
